Ganirelix vs Cetrorelix — Peptide Comparison

Ganirelix vs Cetrorelix — Peptide Comparison Ganirelix vs Cetrorelix — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Ganirelix 250 mcg–500 mcg micrograms Cetrorelix 0.25 mg–3 mg mg Frequency Once daily Administration Subcutaneous injection Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Efficacy Ovulation Control IVF Success Improvement Safety & OHSS Prevention Cycle Flexibility Side Effect Profile Technical Data Molecular Formula C80H113ClN18O13 Molecular Weight 1570.4 g/mol Half-Life 10-12 hours Bioavailability ~91% (subcutaneous injection) CAS Number 124904-93-4 C70H92ClN17O14 1431.06 Da Approximately 2-6 hours (varies by route of administration) ~85% (subcutaneous injection) 100885-89-0 Protocols standard 250 mcg Once daily during the mid-to-late follicular phase Continued daily until the day of hCG administration (typically about 5-9 days) FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4]. starting 0.25 mg Once every 24 hours From stimulation day 5-6 until the day of hCG (about 4-9 days) The FDA-approved multiple-dose plan. A 0.25 mg shot under the skin each day stops an early LH surge during fertility (IVF) ovarian stimulation. [5] 3 mg Single dose (one injection) One dose covers at least 4 days; add 0.25 mg daily after if hCG is delayed The FDA-approved single-dose plan. One 3 mg shot is given when estrogen levels show the follicles are ready (usually stimulation day 7). It protects against an early LH surge for at least 4 days. [5][6] Applications Improving IVF or ICSI success rates Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Preventing premature ovulation during egg retrieval cycles Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Controlling ovarian stimulation in women with unpredictable cycles Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Planning IVF with precise ovulation timing Cetrorelix is particularly well-suited for individuals focused on planning ivf with precise ovulation timing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Preventing premature egg release during controlled stimulation Cetrorelix is particularly well-suited for individuals focused on preventing premature egg release during controlled stimulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing polycystic ovary syndrome (PCOS) during fertility treatment Cetrorelix is particularly well-suited for individuals focused on managing polycystic ovary syndrome (pcos) during fertility treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Mild discomfort at treatment site Injection site reactions (redness, bruising, swelling) Headaches Abdominal pain Pelvic discomfort Nausea Fatigue or dizziness Serious Severe allergic reaction Injection site reactions (redness, itching, swelling) Headache Mild abdominal discomfort Dizziness Allergic reactions (rash, difficulty breathing) Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs Ovarian cysts Vaginal bleeding Mood changes Liver enzyme changes Pelvic pain Research Status FDA Status FDA approved for this use Safety Overview Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted. Contraindications xPregnancy or suspected pregnancy xBreastfeeding xKnown allergies to any medication component xOvarian cysts larger than 3cm Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles. Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients. No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns. Hypersensitivity reactions are rare but possible. xKnown allergy to cetrorelix or any ingredient xPregnancy (it may harm the developing baby) xUndiagnosed vaginal bleeding xSevere liver or kidney disease xLatex allergy (some syringes contain latex) Decision Guide Choose Ganirelix if... Improving IVF or ICSI success rates Preventing premature ovulation during egg retrieval cycles Controlling ovarian stimulation in women with unpredictable cycles Choose Cetrorelix if... Planning IVF with precise ovulation timing Preventing premature egg release during controlled stimulation Managing polycystic ovary syndrome (PCOS) during fertility treatment